

C3G, a Guanine Nucleotide Exchange Factor Bound to Adapter Molecule c-Crk, Has Two Alternative Splicing Forms

Bo Zhai, Hairong Huo, and Kan Liao¹

State Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China


Received June 27, 2001

Two types of C3G cDNA were isolated from mouse 3T3-L1 adipocyte cDNA library. A 114-bp sequence in the middle of C3G cDNA is deleted in the short type cDNA. By RT-PCR analysis, it was found that these two types of C3G mRNA existed in all the mouse tissues. Sequence comparison revealed 88% nucleotide sequence identity between mouse and human C3G cDNA. Comparison of mouse C3G cDNA with the human genome database suggested that this 114-bp sequence comprised an entire exon, and it is confirmed by PCR analysis using mouse genomic DNA and cDNA template. These results indicate that two C3G mRNAs and proteins result from alternative RNA splicing. © 2001 Academic Press

Key Words: C3G; alternative splicing; adapter molecule; guanine nucleotide exchange factor

C3G is a guanine nucleotide exchange factor, which was isolated by its ability of binding to the SH3 domain in adapter molecule c-Crk (1, 2). In C3G molecule, the SH3 domain binding region is located in the middle of the molecule and a CDC25 homologous sequence catalyzing the guanine nucleotide exchange reaction at its C-terminal (1, 2). The function of C3G molecule's N-terminal is not well understood. Recently it was reported that $p130^{\text{Cas}}$, a docking molecule, binds to the N-terminus of C3G molecule via its SH3 domain (3). As a signal molecule, C3G can catalyze guaninenucleotide exchange reaction for Rap1, but not other Ras-family G proteins (4). Activation of C3G occurs through its membrane recruitment (5, 6). This membrane recruitment is believed to be mediated by c-Crk, not by direct interaction of C3G molecule with cell membrane components (5, 6). Thus, the SH3-domain binding region in middle of the molecule is crucial for

¹ To whom correspondence should be addressed. Fax: 86-21-64338357. E-mail: kliao@sunm.shcnc.ac.cn.



As a primary mediating molecule for C3G activation, c-Crk mRNA has two alternative splicing forms, which result in two types of c-Crk protein (8). The large form, c-CrkII, contains one SH2 domain and two SH3 domains with a regulatory phosphorylation tyrosine residue in between the two SH3 domains, whereas the small from, c-CrkI, lacks the C-terminal SH3 domain and the regulatory phosphorylation tyrosine residue. In normal cells, c-CrkI is usually present at much lower level than c-CrkII. Elevated expression of c-CrkI form will lead to the cell transformation (8, 9). It appears that c-CrkI, structurally reassembling to the viral oncoprotein v-Crk, lacks the functional control regulation of c-CrkII. The physiological relevance of the expression of c-CrkI is not clear. Nevertheless, the alternative splicing of c-Crk leads to the change of its functional regulations.

In this report, we identified two mouse C3G mRNA forms from screening library. Further analysis indicated that these two forms of C3G mRNA resulted from different exon splicing.

MATERIALS AND METHODS

Cell culture. The 3T3-L1 preadipocytes were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum and allowed to reach confluence. Differentiation of two-day postconfluent preadipocytes (designated as day 0) was initiated with 1 μ g/ml insulin, 1 μ M dexamethasone (DEX) and 0.5 mM 3-iso-butyl-1-methylxanthine (MIX) in DMEM supplemented with 10% fetal bovine serum (12, 13). After 48 h (day 2), the culture medium was replaced with DMEM supplemented with 10% fetal bovine serum and 1 μ g/ml insulin for additional 48 h, and the cells were then fed every other day with DMEM containing 10% fetal bovine serum. The cytoplasmic triglyceride droplets are visible by day 4 and the cells are fully differentiated by day 6.



A	1 61	CCGCCGCGCC	GCCGCCGCC GCGGCGGAGT	CGCCGGCCGG	CGGCTCGCGG	CCCCGGAGCG	GCGGCTGCGC GGCGAGCGCA
	121	CGAGCCGCGG	CCGCGCGGAG	CCCGCCATGA	CGGCGCGAGT	GTGAGGCGCG	GCGAGCACCG
	181	GTCCAGTAGA	GCGGCGGCG	CGCCGGCCTC	TTATCCCGCA	GCGGCCGGGC	CGGGCCCTGA
							M
	241	TGAGCAGCGG	CCTCGGCCTC	CGGCGCAGCC			GAGAAAGCAG
		S S G	L G L	R R S P	E M S	G K I	E K A D
	301		TTCTCATCTC		CCATGAAGCT		TTCCACTCTC
		S Q R	S H L	S S F T	M K L	M D K CGAGGTGTCG	F H S P
	361		GAGAACACCA R T P	S K K G	K P A	E V S	K I P E
	401	K I K AGAAGCCTGT	R T P GAGCAAAGAG			AGAGGGCTAC	CCTATCCCCT
	421	K P V	S K E	A R D R	F L P	E G Y	P I P L
	481	TGGATCTGGA		GTAGAATTTA			TCCAGGTCTC
	401	D L E	O O A	V E F M	S T S	A V A	S R S O
	541	AGAGGCAGAA		Carried Control of the Control of th		GGAGGTTGTC	PODESCHOOL STATE OF S
	241		N L C	W L E E	KEK	E V V	SALR
	601		GACCATTGTG	GACAAAATGG	CCATTGATAA	GAAGGTTCTG	GAGATGCTCC
	001	Y F K	T I V	D K M A	I D K	K V L	E M L P
	661	CGGGGTCAGC	CAGCAAGGTG	CTGGAGGCCA	TCTTACCCCT	GGTGCAGACT	GACCCTCGGA
		g s A	S K V	L E A I	L P L	V Q T	D P R I
	721	TCCAGCACAG	CTCAGCCCTC	TCCTCCTGTT	ATAGCCGAGT	ATACCAGAGC	
		Q H S	S A L	S S C Y	S R V	Y Q S	L A N L
	781	TTATCCGATG	GTCTGACCAG				
		I R W	S D Q	V M L E	G V N	S E D	K E M V
	841	TGACAACTGT		ATCAAAGCTG		V K E	CTAGTGAGGC L V R L
	0.01	T T V	K G V GAAGCAGGGG	I K A V			
	901	TAACCATTGA T I E	K Q G	R P S P	T S P	V K P	S S P A
	961		TGATGGCCAG				
	901	S K P	D G O	P E L P	L T D	R E M	E I L N
1	1021		AAGTGTGTCA		AACTGCTCCC	AGACTCCACC	AGTGAAGAGG
-		K T T	s v s	P S A E	L L P	D S T	S E E V
-	1081	TCGCACCCC	CAAGCCCCCT	TTACCTGGCA	TCCGGGTGGT	TGATAACAGT	CCACCAGCAT
		A P P	K P P	L P G I	R V V	D N S	PPAL
1	1141					GGTGGCTGTG	
		PPK	K R Q	S A P S	P T R	V A V	V A P M
-	1201	TGAGTCGGGC	TACCAGTGGC		V G I	CAATAGGCAG N R O	D F D V
	1061	S R A	T S G CACCCAGAGG	S S L P			
	1261	E C Y	T O R	R L S G	G S R	S C G	G E S P
	1321		CCCCTGCAGC		-		
-	1321	R L S	P C S	S T G K	L S R	S D E	Q L S S
	1381	CCCTGGACAG	GGATAGTGGG	CAGTGCTCAC	GGAACACAAG	CTGTGAAACA	CTAGATCACT
		L D R	D S G	Q C S R	N T S	C E T	L D H Y
	1441	ACGACCCCGA	CTATGAATTC	CTCCAGCAAG	ATCTCTCCAA	TGCAGACCAG	ATCCCTCCAC
		D P D	Y E F	L Q Q D		A D Q	I P P Q
	1501		TAACCTCAGC				
		A A C	N L S	P L P E		E S G	P P F L
	1561		TTTCCAGCTG				Q Q T D
	1 () 1	G H P	F Q L TGCCCTTCCG				
	1621	T P P	A L P	E K K R		V S O	T T D S
	1681		CAGGGTGTCC			~	
	T 00 T	S G C	R V S	Y E R H		Y D N	I S E G
	1741		GAACCCAGTC				GCTGCTGTCC
	- -	D L O	N P V	P V Q P	V P Y	PPF	A A V L
	1801	TGCCCTTTCA	GCAGGGAGCT			TGTGGGTGAT	
		P F Q		S S A S		V G D	F S V P

FIG. 1. Nucleotide and amino acid sequences of mouse C3G cDNA. (A) The amino acid sequence is shown under the nucleotide sequence using the standard single-letter code. The boxed nucleotide and overshadowed amino acid sequences indicate the region, which is deleted in the short type of C3G cDNA. (B) Comparison of human and mouse C3G cDNA. The exons of human C3G cDNA were obtained from search human genome database with human C3G cDNA. Human C3G cDNA exon 3 (overshadow) corresponds to the deleted sequence in mouse cDNA. The bold and underlined nucleotide sequences are two pairs of primers (P1-P1'and P2-P2') used for PCR analysis.

```
CTGAGTTGGC GGGTGACACA GAGAAGCCAC CTCCTCTACC AGAGAAGAAG AACAAGCACA
1861
               G D T E K P P P L P E K K N K H M
       E L A
      TGCTGGCCTA CATGCAACTG CTGGAGGACT ACTCAGAGCC ACAGCCCTCC ATGTTCTACC
1921
       T. A Y
               M O L
                       LEDYSEP
                                          Q P S M F Y Q
      AGACACCGCA GAGTGAGCAC ATCTACCAGC AGAAGAACAA GATGCTCATG GAGGTGTACG
1981
                                  K N K
                                           M L M E V Y G
               SEH IYOO
       T P O
      GCTTCAGCGA GTCCTTCTGC GGTAGTGATT CCACGCAGGA GCTGGCCCCT CCACCCGCTC
2041
                                           L A P
               S F C G S D S
                                  T O E
                                                   PPAL
       F S E
      TGCCCCCCAA GCAACGGCAG CTGGAACCAC CATCTGGGAA GGACGGACAT CCCAGAGATC
2101
               Q R Q L E P P
                                  S G K
                                           D G H
                                                   PRDP
       PPK
      CTTCGGTCAG CAGTGCATCT GGGAAGGACA GCAGAGAAAA TGGGGAAAGG TCCCCAAAGT
2161
               S A S G K D S
                                  R E N
                                          GER SPK S
       s v s
      CACTGGATGG TCTGGAGTCA GCGCAGTCAG AAGAGGAAGT GGATGAACTG TCCCTCATTG
2221
                       A Q S E E E V
                                           D E L
                                                  SIID
       L D G
               L E S
      ACCACAATGA AATTATGGCC AGGCTGACAC TCAAGCAAGA GGGTGATGAT GGGCCAGATG
2281
               I M A R L T L K Q E G D D G P D V
       H N E
      TTCGTGGTGG TTCAGGAGAC ATCTTACTGG TCCATGCTAC TGAGACAGAC AGAAAAGACC
2341
                                          E T D
                                                  RKDL
               S G D
                       ILLVHAT
       R G G
      TGGTGCTGTA CTGTGAAGCC TTCCTGACCA CCTACAGGAC CTTCATCAGC CCGGAGGAGC
2401
               CEA
                       F L T T
                                   Y R T
                                          F I S
                                                  PEEL
       V T, Y
      TCATCAAGAA GCTGCAGTAC CGGTACGAGA AGTTCTCTCC CTTTGCTGAC ACGTTCAAGA
2461
                                  F S P
                                          F A D
                                                   TFKK
               TOYRYEK
       TKK
      AGCGAGTGAG CAAGAACACA TTCTTTGTGC TGGTTCGAGT GGTGGATGAG CTCTGCCTGG
2521
                                           V D E
                                                   L C L V
               K N T
                       F F V L
                                  V R V
       R V S
      TGGAGCTGAC AGAGGAGATC CTGAAGCTGC TGATGGAGCT GGTCTTCCGC CTAGTGTGCA
2581
               E E I L K L L M E L
       E L T
                                          VFR
                                                   L V C S
      GCGGAGAGCT CAGCCTGGCC AGAGTCCTCC GGAAGAACAT TCTGGACAAG GTGGACCAGA
2641
                       RVLRKNI
                                          L D K
                                                  V D O K
               S L A
       G E L
      AGAAGCTGCT CAGGTGTGCC CATTCCGACC AGCCTCTGGC AGCCAGGGGT GTTGCAGCCA
2701
                                          A R G V A A R
                       H S D O P L A
               R C A
      GGCCAGGAAC CTTGCATGAT TTCCACAGCC ACGAGATAGC TGAGCAGCTG ACACTGCTGG
2761
                        F H S H E I A
                                          EQLTLLD
       PGT
               T. H D
      ATGCCGAGCT TTTCTACAAG ATAGAGATTC CTGAAGTTTT GCTTTGGGCC AAAGAGCAGA
2821
                                                  K E Q N
                       I E I P E V L
                                          L W A
       A E L
               F Y K
      ATGAGGAGAA GAGTCCCAAT CTGACCCAGT TCACAGAGCA CTTCAACAAC ATGTCCTACT
2881
              SPN
                       L T O F
                                  T E H
                                          F N N
                                                   M S Y W
       E E K
      GGGTGCGGTC CATCATCATG CTGCAGGAGA AGGCCCAGGA CCGGGAGAGG CTGCTCCTCA
2941
                       LOEKAOD
                                          R E R
       V R S
               TTM
      AGTTCATCAA GATCATGAAG CACCTGCGCA AGCTCAACAA CTTCAACTCC TACCTGGCCA
3001
                       H L R K L N N F N S
                                                   Y L A
               I M K
       FIK
      TCCTCTCAGC ACTAGACTCG GCCCCCATCC GCAGACTGGA GTGGCAGCGG CAGACCTCAG
3061
               L D S A P I R R L E W Q R
                                                  O T S E
       L S A
      AGGGCCTGGC TGAGTACTGC ACATTGATTG ACAGCTCATC CTCCTTCCGA GCCTACCGGG
3121
                       T L I D
                                  S S S S F R
                                                  AYRA
                E Y C
      CTGCTCTCTC AGAGGTGGAG CCCCCATGTA TCCCATACCT AGGTCTGATT CTGCAAGACC
3181
                       PPCIPYLGLI LQDL
                E V E
      TGACCTTCGT TCACCTGGGA AACCCAGATT ATATTGACGG GAAAGTAAAC TTCTCCAAGC
3241
                       N P D Y
                                  I D G K V N
                                                   FSKR
       T F V
                H L G
      GGTGGCAACA GTTCAACATA TTGGACAGCA TGCGGTGCTT CCAGCAGGCG CACTATGAAA
3301
               F N I L D S M
                                   R C F
                                           Q Q A
                                                  H Y E I
       W Q Q
      TCCGGAGAAA CGACGACATC ATAAATTTCT TCAATGACTT CAGTGACCAC CTGGCCGAGG
3361
        RRN DDI INFF NDF
                                           SDH
      AAGCCCTGTG GGAACTCTCT CTGAAGATCA AGCCTAGGAA CATAACAAGG CGGAAAACAG
3421
       ALWELS LKIK PRN I TR
                                                  RKTD
      ACCGCGAAGA GAAGACCTAG GAGCAGGCTG GCTGTGAGAA CGCTCAAGCA GCCAGGAGAG
3481
        REEKT*
                         (1086 AA)
      GACCTGGACC ATCCCAGCCT CAGCCTGTCC ATGCCTGGCT GTGTGGCAGC ACCTGAGTCT
3541
      CCTGGCCGGT CTCCTGCCTC CTTCCCTATG GCTAAAGTCC CAGGGTTCAC AATGAGCTGG
3601
      CTGGCAGGCC TCAGGGCTGG CTTGTGTACT GGTGGCCCCT GGTCTGGTTT TGTTTTCTGT
3661
      TTTCTGTCAG TGCTCCCTCC TGTTCCCTCC TCTCCCCTGC G (3761bp)
3721
```

FIG. 1—Continued

В	HUMAN	${\tt ACTCTCAGCGTTCTCATCTCTCCTTCACCATGAAGCTGATGGACAAATTCCACTCaCCCAAA}$
	MOUSE	ACTCTCAGCGTTCTCATCTCCTCCTTCACCATGAAGCTGATGGACAAATTCCACTCtCCCAAA
		EXON 2
	HUMAN	${\tt ATCAAGAGAACgCCATCaAAGAAGGGAAAaCCAGCtGAGGTGTCcgtaAAGATTCCaGAGAAGCC}$
	MOUSE	ATCAAGAGAACaCCATCcAAGAAGGGAAAgCCAGCcGAGGTGTCGAAGA <u>TTCCtGAGAAGCC</u>
		P2
	HUMAN	${\tt TGTGAaCAAAGAGGCAAcAGACAGATTTCTACCAGAGGGCTACCCTCTCCCCTTGGATCTGGAGC}$
	MOUSE	$\underline{\mathtt{TGTGAgC}}\mathtt{AAA}\underline{\mathtt{GAGGCAAgAGACAGATTTC}}\mathtt{TACCAGAGGGCTACCCTTTCCCCTTGGATCTGGAGC}$
		P1 EXON 3
	HUMAN	AGCAGGCAGTAGAATTTATGTCCACCAGTGCTGTGGCTTCCAGGTCTCAaAGGCAGAAGAACCTG
	MOUSE	AGCAGGCAGTAGAATTTATGTCCACCAGTGCTGTGGCTT <u>CCAGGTCTCAGAGGCAGAAG</u> AA <u>CCTG</u>
	MOUSE	AGCAGGCAGTAGAATTTATGTCCACCAGTGCTGTGGCTT <u>CCAGGTCTCAGAGGCAGAAG</u> AA <u>CCTG</u>
	MOUSE HUMAN	
		P1'
	HUMAN	P1' aGCTGGCTGGAGGAGAAAGAAAGAAAGTTGTCAGTGCCCTGCGCTACTTTAAGACCATTGTGGA
	HUMAN	P1' aGCTGGCTGGAGGAGAAGGAAGGAAGTTGTCAGTGCCCTGCGCTACTTTAAGACCATTGTGGA tGCTGGCTGGAGGAGAAAGAAAGAGAAGGAGGTTGTCAGTGCCCTTGCGCTACTTTAAGACCATTGTGGA
	HUMAN MOUSE	agctggctggaggagaaagagaaggattgtcagtgccctgcgctactttaagaccattgtgga tgctggctggaggagaaagagagaggttgtcagtgccttgcgctactttaagaccattgtgga p2' EXON 4
	HUMAN MOUSE HUMAN	agctggctggaggagaaagaaggaagttgtcagtgccctgcgctactttaagaccattgtgga tgctggctggaggagaaagaaggaggttgtcagtgccttgcgctactttaagaccattgtgga p2' EXON 4 CAAAATGGCAATTGATAAGAAGGTaCTGGAGATGCTtCCaGGGTCAGCCAGCAAGGTGCTGGAGG
	HUMAN MOUSE HUMAN	agctggctggaggagaaagaaggaagttgtcagtgccctgcgctactttaagaccattgtgga tgctggctggaggagaaagaaggaggttgtcagtgccttgcgctactttaagaccattgtgga p2' EXON 4 CAAAATGGCAATTGATAAGAAGGTaCTGGAGATGCTtCCaGGGTCAGCCAGCAAGGTGCTGGAGG
	HUMAN MOUSE HUMAN MOUSE	agctggctggaggagaaagagaaggaagttgtcagtgccctgcgctactttaagaccattgtgga tgctggctggaggagaaagagagggttgtcagtgccttgcgctactttaagaccattgtgga p2' EXON 4 CAAAATGGCaATTGATAAGAAGGTaCTGGAGATGCTtCCaGGGTCAGCCAGCAAGGTGCTGGAGG CAAAATGGCcaTTGATAAGAAGGTtCTGGAGATGCTtcCcgGGGTCAGCCAGCAAGGTGCTGGAGG

FIG. 1—Continued

Isolation of mouse C3G cDNA clones. The human C3G cDNA was labeled with $[\alpha^{-3^2}P]dATP$ by random-priming methods (10) and used as probe to screen $\sim \! 1$ million λ phage plaques of a day 5 3T3-L1 adipocyte (mouse cell line) cDNA library (11). The hybridization was carried out in 20% formamide, $4\times$ SSC (standard saline citrate), $1\times$ Denhardt's solution, 1% SDS, 50 $\mu g/ml$ salmon sperm DNA, 0.5 mg/ml sodium pyrophosphate, and 50 mM sodium phosphate, pH 7.0, at $42^{\circ}C$ overnight, and washing in 0.1% SDS and $0.1\times$ SSC 3 times at $50^{\circ}C$.

Isolation of DNA and PCR analysis. Chromosomal DNA from one 10-cm dish of confluent 3T3-L1 preadipocytes was isolated by the method of Wigler et al. (14). One microgram genomic DNA was used as template for PCR analysis with primers as described under Results. The DNA amplification was carried out in 50 μl containing 10 mM KCl, 8 mM (NH₄)₂SO₄, 10 mM Tris–HCl, pH 9.0, 1.5 mM MgCl₂, 200 μM dNTPs, 1 μM each primers and 2.5 units of Taq DNA polymerase. The reaction was conducted for 30 cycles (94°C for 1 min, 54°C for 0.5 min and 72°C for 1 min). The products were analyzed by agarose or polyacrylamide gel electrophoresis.

Isolation of mRNA and RT-PCR analysis. Total RNA was isolated from 2-day postconfluent 3T3-L1 preadipocytes, day 6 3T3-L1 adipocytes and mouse tissues using TRIZOL reagent (GibcoBRL), and total mRNA was isolated from RNA using Polytract mRNA isolation reagent (Promega). One microgram total mRNA was reversed transcribed in 20 μl mixture containing 2 mM oligo (dT $_{\rm 18}$), 1 mM dNTPs, 50 mM Tris–HCl, pH 8.3, 75 mM KCl, 3 mM MgCl $_{\rm 2}$, 10 mM DTT and 200 units MMLV reverse transcriptase at 42°C for 1 h. The reaction was terminated by incubating at 75°C for 10 min and cDNA equivalent for 50 ng mRNA was used for PCR analysis.

C3G protein analysis. Total cellular protein was extracted from 3T3-L1 cells and used for Western blot analysis. 3T3-L1 cell monolayer was washed twice with ice-cold phosphate-buffered saline (PBS), pH 7.5 and then lysed directly in boiling $1\times$ Laemmli SDS sample buffer containing 20 mM dithiolthretol. Cellular protein was subjected to 8% SDS-PAGE and transferred to Immobilon-P mem-

brane. C3G protein was detected with antibody (Santa Cruz) against C3G and visualized by ECL (enhanced chemiluminescence).

RESULTS

Cloning of mouse C3G. Human C3G was isolated by screening expression library with SH3 domains of c-Crk as probe (1, 2). Using human C3G cDNA as probe the mouse C3G cDNA was isolated by screening 3T3-L1 adipocyte cDNA library. Sequence comparison revealed 88% nucleotide sequence identity between human and mouse C3G cDNA at coding region, but less sequence homology at 5' and 3' untranslated region. From 3T3-L1 adipocyte cDNA library, two types of mouse C3G cDNA were identified (Fig. 1A). The long type C3G cDNA contains an extra 114-bp sequence in the coding region over the short type cDNA. The multiple C3G protein bands detected by C3G antibody on Western blot may represent this mRNA variance (Fig. 3C). To ascertain whether this 114-bp sequence represents an alternative mRNA splicing or an aberration of library construction, both mouse and human C3G cDNAs were compared with human genomic sequence database to locate the exon sequences. Database search revealed that on human genomic sequence this 114-bp sequence represents one exon (Fig. 1B). Due to the high degree of homology between mouse and human C3G cDNA sequence, it is likely that this 114-bp sequence is also a single-exon in mouse genomic sequence.




FIG. 2. PCR analysis of mouse C3G genomic gene exon structure. (A) Schematic diagram of PCR using genomic DNA or cDNA as template. Primers P1, P1', P2 and P2' are indicated in Fig. 1B. (B) PCR result. P1 and P2 indicate the primer pairs of P1-P1' and P2-P2' respectively.

Alternative splicing for C3G mRNA. To prove this 114-bp sequence in mouse C3G also represents one exon, PCR analysis was conducted using mouse genomic DNA template and primers designed as that one pair (P1-P1') is on the inside ends of 114-bp region and the other pair (P2-P2') is on the outside ends (Figs. 1B and 2A). As shown in Fig. 2B, using C3G cDNA template both pairs of primers produced PCR products. As expected, a 114-bp DNA fragment was produced by P1 pair primers and a 156-bp fragment was produced by P2 pair primers. However, using mouse genomic DNA template, only the pair of primers at the inside ends (P1 pair) produced the 114-bp DNA fragment, the same as using cDNA template, whereas the outside pair of primers produced no DNA fragment around this size. This result indicated that the cDNA sequences corresponding to the outside pair of primers were located far away in the genomic DNA, while the sequences corresponding to the inside primers were in one exon. Thus, in genomic DNA this 114-bp cDNA sequence is single exon, and the cDNA sequences adjacent to this region were located in the different exons.

Two forms of C3G mRNA in most tissues. mRNA alternative splicing could be ubiquitous, such as c-CrkII and c-CrkI which exist in many tissues (5, 8, 15), or tissue specific, such as mammalian STE20-like kinase 3 (MST3), which has a brain-specific alternative spliced form MST3b (16). To find whether the alternative splicing process for C3G mRNA is a tissue specific

or ubiquitous process, total mRNA from different mouse tissues were isolated and the C3G transcripts were analyzed using RT-PCR. As shown in Fig. 3A. C3G mRNA in all the tissues tested (brain, adipose, heart, kidney, liver, lung, muscle and spleen) had two spliced forms. Thus, alternative splicing for C3G mRNA is not a tissue specific process. Unlike c-Crk alternative splicing process, in which the level of c-CrkII is much higher than that of c-CrkI (15), both long and short forms of C3G mRNA were present in the tissues at a similar level. However, the expression levels of total C3G mRNA in various tissues were very different, high in brain, heart, liver and muscle, and low in adipose, kidney and spleen. Interestingly, 3T3-L1 preadipocyte differentiation also affected the C3G mRNA splicing process. In preadipocytes, the long C3G mRNA was the predominant form of C3G mRNA (Fig. 3B), while the short C3G mRNA was barely detectable if PCR was carried out in more cycles (result not shown). However, as the cells differentiated into adipocytes, the level of short C3G mRNA increased and two types of C3G mRNA were equally presented in

CL Br. Fat H Kid. Li. Lu. Mu Sp CS




FIG. 3. RT-PCR analysis of C3G mRNA in mouse tissues and 3T3-L1 cell. (A) Two types of C3G mRNA in mouse tissues. The forward primer is 5'ACTCTCAGCGTTCTCATCTC corresponding to the cDNA sequence from bp 301 to 320 and the complement primer is 5'GCTGGTGGACTGTTATCAAC corresponding to the sequence from bp 1119 to 1138. CL refers to control for long form C3G mRNA and CS to control for short form mRNA. Br, Fat, H, Kid, Li, Lu, Mu, and Sp refer to RT-PCR analysis of mRNA from brain, adipose, heart, kidney, liver, lung, muscle and spleen respectively. (B) C3G mRNA in 3T3-L1 preadipocytes and adipocytes. CL and CS are the same as in A. Pre. refers to 3T3-L1 preadipocyte and Adip. to 3T3-L1 adipocyte. (C) Western blot of C3G protein in 3T3-L1 adipocytes.

A

adipocytes. Thus, in mature differentiated tissue cells both types of alternative spliced C3G mRNA existed in similar amount.

DISCUSSION

Protein molecules involved in signal transduction often have several variants by alternative RNA splicing. This alternative splicing increases the structural and possibly functional complexity for signal molecules. For C3G protein, the domain of guanine nucleotide releasing factor is located at the C-terminal and c-Crk's SH3 domain binding motif is in the middle of the molecule (1, 2). So far, the function of C3G's N-terminal is not clear. The alternative splicing for C3G RNA results in a deletion of 38 amino acids in the nonfunctional N-terminal region. Thus, the functional implication of this RNA alternative splicing is not known.

The change of C3G RNA splicing during 3T3-L1 preadipocyte differentiation is a little puzzling. Since the difference between these two C3G mRNAs are not big enough for them to be resolved on Northern blot, their relative amounts were only determined by RT-PCR. It should be pointed out in preadipocytes the short C3G mRNA still exists. Thus, the change of RNA splicing during differentiation may only reflect a quantitative change not a fundamental change in the RNA splicing process.

ACKNOWLEDGMENTS

We are most grateful to Dr. M. Matsuda for providing the human C3G cDNA. This work was supported by Research Grant 39825107 from the Chinese National Nature Sciences Foundation and grants from the Chinese Academy of Sciences. The nucleotide sequence reported in this paper has been submitted to the GenBank Database under Accession No. AF348669.

REFERENCES:

- Tanaka, S., Morishita, T., Hashimoto, Y., Hattori, S., Nakamura, S., Shibuya, M., Matuoka, K., Takenawa, T., Kurata, T., Nagashima, K., and Matsuda, M. (1994) C3G, a guanine nucleotidereleasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. *Proc. Natl. Acad.* Sci. USA 91, 3443–3447.
- Knudsen, B. S., Feller, S. M., and Hanafusa, H. (1994) Four proline-rich sequences of the guanine-nucleotide exchange factor

- C3G bind with unique specificity to the first Src homology 3 domain of Crk. *J. Biol. Chem.* **269**, 32781–32787.
- Krisch, K., Georgescu, M., and Hanafusa, H. (1998) Direct binding of p130^{cas} to the guanine nucleotide exchange factor C3G. J. Biol. Chem. 273, 25673–25679.
- Gotoh, T., Hattori, S., Nakamura, S., Kitayama, H., Noda, M., Takai, Y., Kaibuchi, K., Matsui, H., Hatase, O., Takahashi, H., Kurata, T., and Matsuda, M. (1995) Identification of Rap1 as a target for the Crk SH3 domain-binding guaninie nucleotidereleaesing factor C3G. Mol. Cell. Biol. 15, 6746-6753.
- Kiyokawa, E., Mochizuki, N., Kurata, T., and Mateuda, M. (1997) Role of Crk oncogene product in physiologic signaling. Crit. Rev. Oncogenesis 8, 329-342
- Ichiba, T., Kuraishi, Y., Sakai, O., Nagata, S., Groffen, J., Kurata, T., Hattori, S., and Matsuda, M. (1997) Enhancement of guanine-nucleotide exchange activity of C3G for Rap1 by the expression of Crk, CrkL and Grb2. *J. Biol. Chem.* 272, 22215–22220.
- 7. Jin, S., Zhai, B., Qiu, Z, Wu, J., Lane, M. D., and Liao, K. (2000) c-Crk, a substrate of the insulin-like growth factor-1 receptor tyrosine kinase, functions as early signal mediator in the adipocyte differentiation process. *J. Biol. Chem.* **275**, 34344–34352.
- Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. (1992) Two species of human CRKcDNA encode proteins with distinct biological activities. *Mol. Cell. Biol.* 12, 3482–3489.
- Matsuda, M., Mayer, B., and Hanafusa, H. (1991) Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins. *Mol. Cell. Biol.* 11, 1607–1613.
- Feinberg, A. P., and Vogelstein, B. (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132, 6–13
- Kaestner, K. H., Ntambi, J. M., Kelly, T. J., Jr., and Lane, M. D. (1989) Differentiation-induced gene expression in 3T3-L1 preadipocytes: A second differentially-expressed gene encoding stearoyl-CoA desaturase. J. Biol. Chem. 264, 14755–14761.
- Student, A. K., Hsu, R. Y., and Lane, M. D. (1980) Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. J. Biol. Chem. 255, 4745–4750.
- Reed, B. C., and Lane, M. D. (1980) Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes. *Proc.* Natl. Acad. Sci. USA 77, 285–289.
- Wigler, M., Sweet, R., Sim, G. K., Wold, B., Pellicer, A., Lacy, E., Maniatis, T., Silverstein, S., and Axel, R. (1979) Transformation of mammalian cells with genes from procaryotes and eucaryotes. *Cell* 16, 777–785.
- Feller, S. M., Posern, G., Voss, J., Kardinal, C., Sakkab, D., Zheng, J., and Knudsen, B. S. (1998) Physiological signals and oncogenesis mediated through Crk family adapter proteins. *J. Cell. Physiol.* 177, 535–553.
- Zhou, T., Ling, K., Guo, J., Zhou, H., Wu, Y., Jing, Q., Ma, L., and Pei, G. (2000) identification of a human brain-specific isoform of mammalian STE20-like kinase 3 that is regulated by cAMPdependent protein kinase. *J. Biol. Chem.* 275, 2513–2519.